# Recombinant West Nile Virus Vaccine Adjuvanted with SLA-LSQ Optimize Formulation of VSA Adjuvant

> **NIH NIH N44** · HAWAII BIOTECH, INC. · 2022 · $2,997,218

## Abstract

The contract supports the development of TLR4 agonist within an oil-in-water emulsion as a vaccine adjuvant.  The adjuvant development activities are being conducted within the context of vaccines to protect against West Nile virus infection.

## Key facts

- **NIH application ID:** 10678482
- **Project number:** 75N93022C00034-0-9999-1
- **Recipient organization:** HAWAII BIOTECH, INC.
- **Principal Investigator:** DAVID CLEMENTS
- **Activity code:** N44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $2,997,218
- **Award type:** —
- **Project period:** 2022-07-05 → 2025-07-05

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10678482

## Citation

> US National Institutes of Health, RePORTER application 10678482, Recombinant West Nile Virus Vaccine Adjuvanted with SLA-LSQ Optimize Formulation of VSA Adjuvant (75N93022C00034-0-9999-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10678482. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*